Wedbush Maintains Underperform on Praxis Precision Medicine, Lowers Price Target to $162

Benzinga Newsdesk www.benzinga.com Negative 96.2%

Neg 96.2% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and lowers the price target from $166 to $162.